title: Initial assessment of impact of adenovirus type 4 and type 7 vaccine on febrile respiratory illness and virus transmission in military basic trainees, March 2012.
abstract: After a 12-year hiatus, military recruit training centers resumed administration of adenovirus type 4 and type 7 vaccine, live, oral (adenovirus vaccine) to trainees beginning in October of 2011. Subsequently, rates of febrile respiratory illnesses (FRI) and adenovirus isolations markedly declined. These findings are consistent with those of a placebo-controlled efficacy trial conducted prior to the vaccine's licensure by the U.S. Food and Drug Administration. Continued surveillance will clarify the longer term impact of vaccine use.
authors.affiliation: U.S. Army Medical Research and Materiel Command Adenovirus Vaccine Integrated Product Team, Fort Detrick, Frederick, MD, USA.
authors.forename: Charles H
authors.initials: CH
authors.lastname: Hoke
authors.forename: Anthony
authors.initials: A
authors.lastname: Hawksworth
authors.forename: Clifford E
authors.initials: CE
authors.lastname: Snyder
mesh_terms: D000258:Adenovirus Infections, Human / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D000260:Adenoviruses, Human; D006801:Humans; D008887:Military Medicine; D008889:Military Personnel; D011159:Population Surveillance; D016730:Program Development; D011634:Public Health; D012141:Respiratory Tract Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D013997:Time Factors; D014481:United States / Q000453:epidemiology; D014765:Viral Vaccines
chemical_list: D014765:Viral Vaccines